65 GSK Annual Report 2017 Strategic report Governance and remuneration Financial statements Investor information Total results Cost of sales Cost of sales as a percentage of turnover was 34.3%, up 1.0 AER growth CER growth Turnover bn percentage points in Sterling terms and up 1.4 percentage points in CER terms compared with 2016.
This primarily reflected the 8% 3% phasing of costs of manufacturing restructuring programmes 30.2bn including non-cash write downs as a result of plant closures and the write down of assets related to the progressive withdrawal of Tanzeum, as well as continued adverse pricing pressure in Pharmaceuticals, primarily Respiratory, and additional supply chain 2015 23.9 investments.
This was partly offset by a more favourable product 2016 27.9 mix across all three businesses, particularly in Pharmaceuticals, reflecting the impact of higher HIV sales, and in Vaccines, reflecting 2017 30.2 the benefit of a settlement for lost third party supply volume and a favourable year-on-year comparison to inventory adjustments in 0 5 10 15 20 25 30 2016.
There was also a continued contribution from integration and restructuring savings in all three businesses.
AER growth CER growth Total operating profit bn Selling, general and administration 57% 39% SG&A costs were 32.0% of turnover, 1.5 percentage points lower than in 2016 in Sterling and CER terms.
This primarily reflected 4.1bn lower restructuring costs and tight control of ongoing operating costs, particularly in Consumer Healthcare, as well as continued cost reductions in Pharmaceuticals, including the benefits of the 2015 10.3 Pharmaceuticals restructuring programme, and integration benefits in Vaccines and Consumer Healthcare.
This was partly offset by an 2016 2.6 increased investment in promotional product support, particularly for new launches in Respiratory, HIV and Vaccines.
2017 4.1 Research and development 0 2 4 6 8 10 12 R&D expenditure was 4,476 million 14.8% of turnover, 23% higher than in 2016 at AER and 19% higher at CER.
This included charges of 106 million from the utilisation of the Priority Review The total results of the Group are set out below.
Voucher in 2017 as well as increased investment in the progression of a number of mid and late-stage programmes.
In addition, there 2017 2016 Growth were higher restructuring costs, primarily as a result of the provision % of % of for future clinical obligations as a result of the progressive m turnover m turnover % CER% withdrawal of Tanzeum and the decision to terminate the rights Turnover 30,186 100 27,889 100 8 3 to sirukumab, and higher intangible asset impairments.
Cost of sales 10,342 34.3 9,290 33.3 11 8 Selling, general and Royalty and other operating income expense administration 9,672 32.0 9,366 33.6 3 1 Net other operating expense of 1,609 million 2016 3,007 Research and million primarily reflected lower accounting charges arising from the development 4,476 14.8 3,628 13.0 23 19 re-measurement of the contingent consideration liabilities related to Royalty income 356 1.1 398 1.4 11 13 the former Shionogi-ViiV Healthcare joint venture and the acquisition Other operating income of the former Novartis Vaccines business, the value attributable to expense 1,965 6.5 3,405 12.2 the Consumer Healthcare Joint Venture put option and the liabilities Operating profit 4,087 13.5 2,598 9.3 57 39 for the Pfizer put option and Pfizer and Shionogi preferential Net finance costs 669 664 dividends in ViiV Healthcare.
The remeasurement charges of Profit on disposal of 2,185 million 2016 3,914 million reflected updated trading interest in associates 94 forecasts and changes in exchange rate assumptions as well as Share of after tax the unwinding of the discount applied to these future liabilities of profits of associates 1,001 million.
They also included charges of 666 million arising and joint ventures 13 5 from the positive impact of US tax reform on the valuation of the Profit before taxation 3,525 1,939 82 58 Consumer Healthcare and HIV businesses.
These charges were Taxation 1,356 877 partly offset by the gain of 250 million on the disposal of the Profit after taxation anaesthesia business to Aspen and royalty income of 356 million for the year 2,169 1,062 100 71 2016 398 million.
Profit attributable to shareholders 1,532 912 Earnings per share p 31.4 18.8 67 36 Earnings per ADS US$ 0.82 0.51 66 GSK Annual Report 2017 Group financial review continued Total results continued Operating profit Profit before taxation Total operating profit was 4,087 million in 2017 compared with Taking account of net finance costs, the profit on disposal of 2,598 million in 2016.
The increase primarily reflected a reduced associates and the share of profit of associates, profit before impact from accounting charges related to the remeasurement of the taxation was 3,525 million compared with 1,939 million in 2016. liabilities for contingent consideration, put options and preferential Taxation dividends.
In addition operating profit benefited from an improved 2017 2016 operating margin driven by sales growth across all three businesses, m m but particularly Vaccines, and a more favourable mix in all three UK current year charge 199 241 businesses.
In Vaccines, there was also a favourable year-on-year Rest of world current year charge 1,928 1,326 comparison with inventory adjustments in 2016 and the benefit of Charge in respect of prior periods 508 149 a one-off settlement in cost of sales.
Continued tight control of Total current taxation 1,619 1,418 ongoing costs and benefits from restructuring and integration also contributed to improved margins in Vaccines and Consumer Total deferred taxation 263 541 Healthcare, but in Pharmaceuticals, the benefits were offset by an Taxation on total profits 1,356 877 overall increase in Pharmaceuticals R&D investment including the A tax charge of 1,356 million on Total profit represented an effective impact of the Priority Review Voucher together with continuing price tax rate of 38.5% 2016 45.2% and included a charge of 1,078 pressure, particularly in Respiratory, and supply chain investments million arising from US tax reform as described in more detail on to support new products.
This was partly offset by a 483 million benefit from Swiss Net finance costs tax reform, arising from the revaluation of deferred tax liabilities on acquired Consumer Healthcare brands to reflect a reduction in the 2017 2016 Finance income m m headline tax rate.
Interest and other income 63 70 Non-controlling interests Fair value movements 2 2 The allocation of earnings to non-controlling interests amounted to 65 72 637 million 2016 150 million, including the non-controlling interest allocations of Consumer Healthcare profits of 415 million Finance expense 2016 203 million and the allocation of ViiV Healthcare profits, Interest expense 720 701 which increased to 187 million 2016 83 million loss including Unwinding of discounts on liabilities 16 16 the impact of changes in the proportions of preferential dividends Remeasurements and fair value movements 4 4 due to each shareholder.
The increase in allocation of ViiV Healthcare profits primarily reflected the impact of lower Other finance expense 6 15 remeasurement charges and the increase in allocation of Consumer 734 736 Healthcare profits reflected improved operating profits together with the benefit of Swiss tax reform in 2017.
Profit on disposal of associates The profit on disposal of associates was 94 million 2016 nil.
Earnings per share This arose from the disposal of our entire shareholdings in two Total earnings per share were 31.4p, compared with 18.8p in 2016. associates, River Vision Development Co. Ltd and JCR The increase reflected the reduced impact of charges arising from Pharmaceuticals Co Ltd. the revaluations of the liabilities for contingent consideration and the put options associated with increases in the Sterling value of Share of after tax profits of associates and joint ventures the Groups HIV and Consumer Healthcare businesses, the benefit The share of profits of associates and joint ventures was 13 million from Swiss tax reform and improved performances by the relevant 2016 5 million.
businesses, partly offset by the charges arising from US tax reform.
Dividends The Board declared four interim dividends resulting in a total dividend for the year of 80 pence, in line with the dividend declared for 2016.
See Note 16 to the financial statements, Dividends.
67 GSK Annual Report 2017 Strategic report Governance and remuneration Financial statements Investor information Adjusting items Divestments, Intangible Intangible significant Total asset asset Major Transaction legal and US tax Adjusted Adjusted results reconciliation results amortisation impairment restructuringrelated other items reform results 31 December 2017 m m m m m m m m Turnover 30,186 30,186 Cost of sales 10,342 546 400 545 80 8,771 Gross profit 19,844 546 400 545 80 21,415 Selling, general and administration 9,672 248 83 9,341 Research and development 4,476 45 288 263 18 3,862 Royalty income 356 356 Other operating income expense 1,965 1,519 220 666 Operating profit 4,087 591 688 1,056 1,599 119 666 8,568 Net finance costs 669 4 8 657 Profit on disposal of associates 94 94 Share of after tax profits of associates and joint ventures 13 13 Profit before taxation 3,525 591 688 1,060 1,599 205 666 7,924 Taxation 1,356 134 176 209 619 251 1,078 1,667 Tax rate 38.5% 21.0% Profit after taxation 2,169 457 512 851 980 456 1,744 6,257 Profit attributable to non-controlling interests 637 42 114 793 Profit attributable to shareholders 1,532 457 512 851 938 456 1,630 5,464 Earnings per share 31.4p 9.4p 10.5p 17.4p 19.2p 9.4 p 33.3p 111.8p Weighted average number of shares millions 4,886 4,886 Divestments, Intangible Intangible significant Adjusted Total asset asset Major Transaction legal and results Adjusted results reconciliation results amortisation impairment restructuringrelated other items revised 31 December 2016 m m m m m m m Turnover 27,889 27,889 Cost of sales 9,290 547 7 297 86 2 8,351 Gross profit 18,599 547 7 297 86 2 19,538 Selling, general and administration 9,366 514 55 8,797 Research and development 3,628 41 13 159 81 28 3,468 Royalty income 398 398 Other operating income expense 3,405 3,914 509 - Operating profit 2,598 588 20 970 3,919 424 7,671 Net finance costs 664 4 8 652 Share of after tax profits of associates and joint ventures 5 5 Profit before taxation 1,939 588 20 974 3,919 416 7,024 Taxation 877 130 5 217 439 170 1,498 Tax rate 45.2% 21.3% Profit after taxation 1,062 458 15 757 3,480 246 5,526 Profit attributable to non-controlling interests 150 487 637 Profit attributable to shareholders 912 458 15 757 2,993 246 4,889 Earnings per share 18.8p 9.4p 0.3p 15.6p 61.6p 5.1 p 100.6p Weighted average number of shares millions 4,860 4,860 68 GSK Annual Report 2017 Group financial review continued Adjusting items continued Intangible asset amortisation and impairment The aggregate impact of unwinding the discount on these future Intangible asset amortisation was 591 million, compared with and potential liabilities was 1,001 million 2016 905 million, 588 million in 2016.
Intangible asset impairments of 688 million including 543 million on the Consumer Healthcare Joint Venture 2016 20 million included impairments related to the progressive put option and 408 million on the contingent consideration related withdrawal of Tanzeum and a number of other commercial and R&D to the former Shionogi-ViiV Healthcare Joint Venture.
The remaining assets following the refocusing of the R&D pipeline during 2017. charge of 598 million was driven by adjustments to trading Both of the amortisation and impairment charges were non-cash forecasts and the impact of updated exchange rate assumptions items.
on those forecasts for the relevant businesses as well as updated multiples used in the valuation of the Consumer Healthcare Joint Major restructuring and integration Venture put option.
Major restructuring and integration charges of 1,056 million have been incurred 2016 970 million.
Non-cash charges Contingent consideration cash payments which are made to were 525 million, primarily reflecting the write down of assets as Shionogi and other companies reduce the balance sheet liability and a result of the decision to withdraw Tanzeum and terminate rights hence are not recorded in the income statement.
Total contingent to sirukumab arising from the establishment of the Groups new consideration cash payments in 2017 amounted to 685 million business priorities, as well as the write down of assets related to 2016 431 million.
This included cash payments made by ViiV reductions in the site network.
Cash charges were 531 million Healthcare to Shionogi in relation to its contingent consideration 2016 704 million, including charges as a result of the decisions liability including preferential dividends which amounted to to withdraw Tanzeum and terminate rights to sirukumab.
payments made were 555 million 2016 1,077 million, including An explanation of the accounting for the non-controlling interests the settlement of certain charges previously accrued, but also in ViiV Healthcare is set out on page 59. reflecting the deferral of some payments into 2018.
Cash payments The impact on profit after tax from transaction-related adjustments of approximately 0.5 billion are expected in 2018.
The programme includes an accounting credit in respect of Swiss tax reform of delivered incremental cost savings in 2017 of 0.7 billion, including 483 million, arising from the revaluation of deferred tax liabilities 0.2 billion of currency benefits.
on acquired Consumer Healthcare brands to reflect a reduction in Charges for the combined restructuring and integration programme the headline Swiss tax rate.
to date are 4.8 billion, of which cash charges are 3.5 billion.
Cash Divestments and other items payments of 3.1 billion have been made to date.
Non-cash charges Divestments and other items included the profit on disposal of the are 1.3 billion.
anaesthesia business to Aspen of 250 million, a number of other An extension to the existing combined programme was agreed by asset disposals, equity investment impairments and certain other the Board in July 2017, with total cash charges of the combined adjusting items.
Significant legal charges of 68 million 2016 programme now expected to be approximately 4.1 billion and 62 million included the benefit of the settlement of existing matters non-cash charges up to 1.6 billion.
The programme has now as well as provisions for ongoing litigation.
Significant legal cash delivered approximately 3.7 billion of annual savings, including payments were 192 million 2016 102 million.
The extended programme is now expected to deliver by 2020 total annual savings of 4.0 billion on US tax reform a constant currency basis, together with an estimated 0.4 billion The enactment of the US Tax Cuts and Jobs Act has resulted in a of currency benefits on the basis of 2017 average exchange rates.
number of additional charges in 2017, which reduced Total earnings by 1,630 million.
Transaction-related adjustments Transaction-related adjustments resulted in a net charge of Firstly, increased valuations of the HIV and Consumer Healthcare 1,599 million 2016 3,919 million.
This primarily reflected businesses due to lower US tax rates resulted in an increase in the accounting charges for the re-measurement of the liability and the related liabilities for contingent consideration and the put options of unwinding of the discounting effects on the contingent consideration 666 million.
related to the acquisition of the former Shionogi-ViiV Healthcare joint Secondly, an additional tax charge of 1,078 million comprised venture, the contingent consideration related to the acquisition of the a reduction in the value of US deferred tax assets held against former Novartis Vaccines business, and the value attributable to the future liabilities, such as pensions, and a current tax credit, together Consumer Healthcare Joint Venture put option held by Novartis.
amounting to 730 million, as well as a charge of 348 million arising These transaction-related adjustments exclude the impact on these on the reserves of subsidiaries of US entities in the Group.
The cash liabilities arising from the implementation of the US Tax Cuts and impact of this latter charge will be spread over eight years from 2018, Jobs Act in 2017 which is set out separately on this page.
with approximately 60% expected to be payable in years six to eight.
2017 2016 These charges were partly offset by an allocation to non-controlling Charge credit m m interests amounting to 114 million, as many of the adjustments Consumer Healthcare Joint Venture put option 986 1,133 related to ViiV Healthcare and the Consumer Healthcare Joint Contingent consideration on former Shionogi-ViiV Venture.
Healthcare Joint Venture including Shionogi These charges represent managements estimates of the impact preferential dividends 556 2,162 of US tax reform on the Group based on the information currently ViiV Healthcare put options and Pfizer preferential available.
As further guidance from the US Treasury on implementation dividends 126 577 of the Act becomes available, particularly with regard to the Contingent consideration on former Novartis repatriation tax provisions, the assumptions underlying these estimates Vaccines business 101 69 could change.
This could result in adjustments to the charges taken Other adjustments 82 22 that could have a material impact on the results of the Group.
Total transaction-related charges 1,599 3,919 69 GSK Annual Report 2017 Strategic report Governance and remuneration Financial statements Investor information Adjusted results Selling, general and administration 2016 AER growth CER growth Turnover bn 2017 revised Growth 8% 3% % of % of m turnover m turnover % CER% 30.2bn Selling, general and administration 9,341 30.9 8,797 31.5 6 1 SG&A costs were 30.9% of turnover, 0.6 percentage points lower 2015 23.9 in Sterling terms than in 2016 and 0.5 percentage points lower on a CER basis.
This primarily reflected tight control of ongoing costs, 2016 27.9 particularly in Consumer Healthcare, continued cost reductions in Pharmaceuticals, including the benefits of the Pharmaceuticals 2017 30.2 restructuring programme, and integration benefits in Vaccines 0 5 10 15 20 25 30 and Consumer Healthcare.
This was partly offset by increased investment in promotional product support, particularly for new launches in Respiratory, HIV and Vaccines.
AER growth CER growth Adjusted operating profit bn Research and development 12% 5% 2017 2016 Growth 8.6bn % of % of m turnover m turnover % CER% Research and development 3,862 12.8 3,468 12.4 11 8 a 2015 5.7 R&D expenditure was 3,862 million 12.8% of turnover, 11% higher a 2016 7.7 than 2016 at AER and 8% higher at CER.
This included a charge of 106 million on the utilisation of the Priority Review Voucher in 8.6 2017 Q2 2017 as well as increased investment in the progression of a 0 2 4 6 8 10 number of mid and late-stage programmes.
Adjusted results now exclude only significant legal c harges per revised definition on m m % CER% page 58.
Prior year figures have been revised.
Discovery 1,020 821 24 21 We use Adjusted results, which is a non-IFRS measure, among Development 1,450 1,249 16 13 other metrics including total results and cash flow generation, Facilities and central support functions 536 558 4 7 to manage the performance of the Group.
Non-IFRS measures Total Pharmaceuticals 3,006 2,628 14 11 may be considered in addition to, but not as a substitute for or Vaccines R&D 621 597 4 2 superior to, information presented in accordance with IFRS.
Consumer Healthcare R&D 235 243 3 7 The definition of Adjusted results is set out on page 58.
Research and development 3,862 3,468 11 8 Cost of sales The growth in Development expenditure was driven by the 2017 2016 Growth progression of a number of mid and late-stage programmes in % of % of m turnover m turnover % CER% HIV, Respiratory and Anaemia, together with the utilisation of the Priority Review Voucher in Q2 2017.
The continuing high growth in Cost of sales 8,771 29.1 8,351 29.9 5 1 Discovery expenditure reflected further investment in the early stage Cost of sales as a percentage of turnover was 29.1%, down 0.9 Oncology portfolio.
percentage points in Sterling terms and down 0.5 percentage Royalty income points in CER terms compared with 2016.
This reflected a more Royalty income was 356 million 2016 398 million.
The favourable product mix across all three businesses, particularly in reduction was primarily due to the patent expiry of Cialis in Q4 2016 Pharmaceuticals, including the impact of higher HIV sales, as well and a catch-up adjustment recorded in Q1 2016. as favourable product mix, the benefit of a settlement for lost third party supply volume and a favourable year-on-year comparison to inventory adjustments in 2016 in Vaccines.
There was also a further contribution from integration and restructuring savings in all three businesses, offset by continued adverse pricing pressure in Pharmaceuticals, primarily Respiratory, and additional supply chain investments.
70 GSK Annual Report 2017 Group financial review continued Adjusted results continued Adjusted operating profit Consumer Healthcare Adjusted operating profit was 8,568 million, 12% AER higher than Consumer Healthcare operating profit was 1,373 million, 23% AER in 2016 and 5% CER higher on a turnover increase of 3% CER.
higher than in 2016 and 11% CER higher on a turnover increase of The Adjusted operating margin of 28.4% was 0.9 percentage points 2%.
The operating margin of 17.7% was 2.2 percentage points higher than in 2016 and 0.4 percentage points higher on a CER higher than in 2016 and 1.3 percentage points higher on a CER basis.
This reflected improved operating leverage driven by sales basis, reflecting tight control of costs, integration synergies, growth and a more favourable mix in all three businesses, together principally in SG&A, partly offset by increased investment in with, in Vaccines, the benefit of a settlement for lost third party supply power brands.
volume and a favourable year-on-year comparison to inventory adjustments in 2016.
There was also continued tight control of Net finance costs ongoing costs across all three businesses as well as benefits from 2017 2016 Finance income restructuring and integration.
This was partly offset by the charge m m of 106 million on the utilisation of the Priority Review Voucher in Interest and other income 63 70 Q2 2017 as well as other increases in R&D investment, continuing Fair value movements 2 2 price pressure, particularly in Respiratory, and supply chain 65 72 investments.
Finance expense Adjusted operating profit by business Interest expense 720 701 Unwinding of discounts on liabilities 4 4 2016 2017 revised Growth Remeasurements and fair value movements 4 4 Margin Margin Other finance expense 6 15 m % m % % CER% 722 724 Pharmaceuticals 8,667 50.2 7,976 49.5 9 3 Pharmaceuticals R&D 2,740 2,488 10 7 Share of after tax profits of associates and joint ventures Pharmaceuticals 5,927 34.3 5,488 34.1 8 1 The share of profits of associates and joint ventures was 13 million Vaccines 1,644 31.9 1,429 31.1 15 11 2016 5 million.
Consumer Adjusted profit before taxation Healthcare 1,373 17.7 1,116 15.5 23 11 8,944 29.6 8,033 28.8 11 4 2016 2017 revised Growth Corporate & other % of % of unallocated costs 376 362 4 3 m turnover m turnover % CER% Adjusted operating Adjusted profit profit 8,568 28.4 7,671 27.5 12 5 before tax 7,924 26.3 7,024 25.2 13 5 Pharmaceuticals Taxation Pharmaceuticals operating profit was 5,927 million, 8% AER higher Tax on Adjusted profit amounted to 1,667 million and represented than in 2016 and 1% CER higher on a turnover increase of 3% CER.
an effective Adjusted tax rate of 21.0% 2016 21.3%.
The operating margin of 34.3% was 0.2 percentage points higher than in 2016 on a Sterling basis but 0.6 percentage points down Non-controlling interests on a CER basis.
This primarily reflected increased R&D investment, The allocation of Adjusted earnings to non-controlling interests including the impact of the utilisation of the Priority Review Voucher amounted to 793 million 2016 637 million, including the in Q2 2017.
The operating margin also reflected increased non-controlling interest allocations of Consumer Healthcare profits investment in new product support, as well as the continued impact of 344 million 2016 288 million and the allocation of ViiV of lower prices, particularly in Respiratory, and the broader transition Healthcare profits, which increased to 414 million 2016 of the Respiratory portfolio, partly offset by a more favourable 324 million including the impact of changes in the proportions product mix, primarily driven by the growth in HIV sales, and the of preferential dividends due to each shareholder.
The increase continued cost reduction benefit of the Groups Pharmaceuticals in allocation also reflected comparison with the reduction in the restructuring programme.
allocation to non-controlling interests due to higher net losses in some of the Groups other entities with non-controlling interests Vaccines in 2016.
Vaccines operating profit was 1,644 million, 15% AER higher than in 2016 and 11% CER higher on a turnover increase of 6% CER.
The Adjusted earnings per share operating margin of 31.9% was 0.8 percentage points higher than in Adjusted EPS of 111.8p was up 11% AER, 4% CER compared 2016 on a Sterling basis and 1.3 percentage points higher on a CER with a 5% CER increase in Adjusted operating profit.
This was primarily driven by improved product mix, the benefit of a settlement for lost third party supply volume and a favourable year-on-year comparison with inventory adjustments in 2016, together with continued restructuring and integration benefits.
This was partly offset by increased SG&A resources to support business growth and new launches, increased supply chain costs and lower royalty income.
71 GSK Annual Report 2017 Strategic report Governance and remuneration Financial statements Investor information Cash generation and conversion A summary of the consolidated cash flow statement is set out below.
Reconciliation of net cash inflow from operating activities to free cash flow 2017 2016 A reconciliation of net cash inflow from operating activities, which is m m the closest equivalent IFRS measure to free cash flow, is shown Net cash inflow from operating activities 6,918 6,497 below.
Net cash outflow from investing activities 1,443 1,269 2016 Net cash outflow from financing activities 6,380 6,392 2017 revised m m Decrease in cash and bank overdrafts 905 1,164 Net cash inflow from operating activities 6,918 6,497 Cash and bank overdrafts at beginning of year 4,605 5,486 Purchase of property, plant and equipment 1,545 1,543 Decrease in cash and bank overdrafts 905 1,164 Purchase of intangible assets 657 809 Exchange adjustments 100 283 Proceeds from sale of property, plant and equipment 281 98 Cash and bank overdrafts at end of year 3,600 4,605 Interest paid 781 732 Cash and bank overdrafts at end of year Interest received 64 68 comprise: Dividends from associates and joint ventures 6 42 Cash and cash equivalents 3,833 4,897 Contingent consideration paid reported in Overdrafts 233 292 investing activities 91 73 3,600 4,605 Contribution from non-controlling interests 21 Distributions to non-controlling interests 779 534 The net cash inflow from operating activities for the year was Free cash flow 3,437 3,014 6,918 million 2016 6,497 million.
The increase primarily reflected improved operating profit performance, as well as a positive Future cash flow currency benefit, partly offset by increased working capital reflecting Over the long term, we expect that future cash generated from the building of inventory in advance of new product launches, operations will be sufficient to fund our operating and debt servicing increased contingent consideration payments and legal settlements.
costs, normal levels of capital expenditure, obligations under existing licensing agreements, expenditure arising from restructuring Total cash payments to Shionogi in relation to the ViiV Healthcare programmes and other routine outflows including tax, pension contingent consideration liability in the year were 671 million, of contributions and dividends, subject to the Principal risks and which 587 million was recognised in cash flows from operating uncertainties discussed on pages 257 to 266.
We may from time activities and 84 million was recognised in contingent consideration to time have additional demands for finance, such as for acquisitions, paid within investing cash flows.
These payments are deductible for including potentially acquiring increased ownership interests in the tax purposes.
ViiV Healthcare and the Consumer Healthcare businesses where Capital expenditure and financial investment minority shareholders hold put options.
We have access to multiple Cash payments for tangible and intangible fixed assets amounted sources of liquidity from short and long-term capital markets and to 2,202 million 2016 2,352 million and disposals realised financial institutions for such needs, in addition to the cash flow 807 million 2016 453 million.
Cash payments to acquire equity from operations.
investments of 80 million 2016 96 million were made and sales Investment appraisal and capital allocation of equity investments realised 64 million 2016 683 million.
We have strengthened our framework for capital allocation, Free cash flow including the creation of a new board to govern the allocation of Free cash flow is the amount of cash generated by the business capital between our businesses.
We utilise a consistent cash return after meeting our obligations for interest, tax and dividends paid to on invested capital CROIC methodology to prioritise investment non-controlling interests, and after capital expenditure on property, across the Group as a whole, so that we can more effectively plant and equipment and intangible assets.
compare the returns from each of the businesses as we allocate capital between them.
We also consider the impact on EPS and 2017 2016 our credit profile where relevant.
m m The discount rate used to perform financial analyses is decided Free cash inflow 3,437 3,014 internally, to allow determination of the extent to which investments cover our cost of capital.
For individual investments the discount rate Free cash flow was 3,437 million for the year 2016 3,014 may be adjusted to take into account specific country, business or million.
The increase primarily reflected improved operating profit project risk.
performance, as well as a positive currency benefit and increases in returns and rebates, partly offset by increased working capital, Working capital reflecting seasonal factors and the building of inventory in advance 2017 2016 of new product launches, increased contingent consideration Working capital percentage of turnover % 22 22 payments, the purchase of the Priority Review Voucher, increased dividends to non-controlling interests, including a catch up Working capital conversion cycle days 191 193 adjustment, and higher legal settlements.
Free cash flow in 2016 The reduction of two days in 2017 compared with 2016 was was also impacted by the costs of acquiring the HIV Clinical assets predominantly due to a beneficial impact from exchange of from BMS for 221 million.
approximately seven days, partly offset by a build in inventory in advance of new product launches and an increase in trade receivables from higher sales.
72 GSK Annual Report 2017 Group financial review continued Financial position and resources Property, plant and equipment 2017 2016 m m Our business is science-based, technology-intensive and highly Assets regulated by governmental authorities.
We allocate significant financial resources to the renewal and maintenance of our property, Non-current assets plant and equipment to minimise risks of interruption to production Property, plant and equipment 10,860 10,808 and to ensure compliance with regulatory standards.
A number of Goodwill 5,734 5,965 our processes use hazardous materials.
Other intangible assets 17,562 18,776 The total cost of our property, plant and equipment at 31 December Investments in associates and joint ventures 183 263 2017 was 21,719 million, with a net book value of 10,860 million.
Other investments 918 985 Of this, land and buildings represented 4,270 million, plant and Deferred tax assets 3,796 4,374 equipment 4,132 million and assets in construction 2,458 million.
Derivative financial instruments 8 In 2017, we invested 1,584 million in new property, plant and Other non-current assets 1,413 1,199 equipment.
This was mainly related to a large number of projects Total non-current assets 40,474 42,370 for the renewal, improvement and expansion of facilities at various worldwide sites.
Property is mainly held freehold.
New investment is Current assets financed from our liquid resources.
At 31 December 2017, we had Inventories 5,557 5,102 contractual commitments for future capital expenditure of 584 Current tax recoverable 258 226 million and operating lease commitments of 1,045 million.
We Trade and other receivables 6,000 6,026 believe that our property and plant facilities are adequate for our current needs.
Derivative financial instruments 68 156 Liquid investments 78 89 We observe stringent procedures and use specialist skills to Cash and cash equivalents 3,833 4,897 manage environmental risks from our activities.
Environmental issues, sometimes dating from operations now modified or discontinued, Assets held for sale 113 215 are reported under Environmental sustainability on page 61 and in Total current assets 15,907 16,711 Note 45 to the financial statements, Legal proceedings.
Total assets 56,381 59,081 Goodwill Liabilities Goodwill decreased during the year to 5,734 million at 31 Current liabilities December 2017, from 5,965 million.
The decrease primarily Short-term borrowings 2,825 4,129 reflected the impact of exchange movements.
Contingent consideration liabilities 1,076 561 Other intangible assets Trade and other payables 20,970 11,964 Other intangible assets include the cost of intangibles acquired Derivative financial instruments 74 194 from third parties and computer software.
The net book value of Current tax payable 995 1,305 other intangible assets as at 31 December 2017 was 17,562 million Short-term provisions 629 848 2016 18,776 million.
The decrease in 2017 reflected the impact Total current liabilities 26,569 19,001 of exchange movements and the amortisation and impairment of existing intangibles of 934 million and 680 million respectively, Non-current liabilities partly offset by the development costs capitalised during the year Long-term borrowings 14,264 14,661 of 251 million and other additions of 454 million.
Corporation tax payable 411 Investments in associates and joint ventures Deferred tax liabilities 1,396 1,934 We held investments in associates and joint ventures with a carrying Pensions and other post-employment benefits 3,539 4,090 value at 31 December 2017 of 183 million 2016 263 million.
Other provisions 636 652 The market value at 31 December 2017 was 372 million 2016 Contingent consideration liabilities 5,096 5,335 502 million.
The largest of these investments was in Innoviva Inc. Other non-current liabilities 981 8,445 which had a book value at 31 December 2017 of 147 million Total non-current liabilities 26,323 35,117 2016 138 million.
The market value at 31 December 2017 Total liabilities 52,892 54,118 was 336 million.
See Note 20 to the financial statements Investments in associates and joint ventures.
Net assets 3,489 4,963 Equity Other investments We held other investments with a carrying value at 31 December Share capital 1,343 1,342 2017 of 918 million 2016 985 million.
The decrease in the Share premium account 3,019 2,954 carrying value during the year was primarily due to the impact of Retained earnings 6,477 5,392 exchange movements.
The most significant of the investments held Other reserves 2,047 2,220 at 31 December 2017 was in Theravance Biopharma, Inc. which Shareholders equity 68 1,124 had a book value at 31 December 2017 of 199 million 2017 Non-controlling interests 3,557 3,839 248 million.
The other investments included equity stakes in companies with which we have research collaborations, which Total equity 3,489 4,963 provide access to biotechnology developments of potential interest and interests in companies that arise from business divestments.
73 GSK Annual Report 2017 Strategic report Governance and remuneration Financial statements Investor information Financial position and resources continued Derivative financial instruments: assets Pensions and other post-employment benefits We had current derivative financial instruments held at fair value We account for pension and other post-employment of 68 million 2016 156 million and non-current derivative arrangements in accordance with IAS 19.
The deficits, financial instruments held at fair value of 8 million 2016 nil.
net of surpluses before allowing for deferred taxation were The majority of these financial instruments related to foreign 1,505 million 2016 2,084 million on pension arrangements exchange contracts both designated and not designated as and 1,496 million 2016 1,693 million on unfunded postaccounting hedges.
The decreases in the deficits were predominantly driven by special funding contributions to the Inventories UK and US schemes and significant UK asset gains partly Inventory of 5,557 million increased from 5,102 million in 2016. offset by lower discount rates that we used to discount the The increase primarily reflected inventory build in advance of new value of the liabilities.
Other non-current liabilities Trade and other receivables Other non-current liabilities amounted to 981 million at Trade and other receivables of 6,000 million decreased from 31 December 2017 2016 8,445 million.
This decrease from 6,026 million in 2016, primarily reflecting exchange movements 2016 reflects the reclassification of the Consumer Healthcare put partly offset by the impact of higher sales.
option to current liabilities during the year.
Deferred tax assets Contingent consideration liabilities Deferred tax assets of 3,796 million decreased from 4,374 million Contingent consideration liabilities amounted to 6,172 million at in 2016 primarily as a result of the revaluation of existing deferred tax 31 December 2017 2016 5,896 million, of which 5,542 million assets to reflect the lower headline US tax rate following enactment 2016 5,304 million represented the estimated present value of US tax reform, partly offset by an increase in deferred tax assets of amounts payable to Shionogi relating to ViiV Healthcare and related to intra-Group profit on inventory.
584 million 2016 545 million represented the estimated present value of contingent consideration payable to Novartis related Derivative financial instruments: liabilities to the Vaccines acquisition.
The liability due to Shionogi included We held current derivative financial instruments at fair value of 216 million in respect of preferential dividends.
The liability for 74 million 2016 194 million.
This primarily related to foreign preferential dividends due to Pfizer at 31 December 2017 was exchange contracts both designated and not designated as 17 million.
An explanation of the accounting treatment of our accounting hedges.
interests in ViiV Healthcare is set out on page 59.
Trade and other payables Net debt Trade and other payables amounting to 20,970 million increased 2017 2016 from 11,964 million in 2016, reflecting the reclassification of the m m Consumer Healthcare put option of 8,606 million from non-current Cash, cash equivalents and liquid investments 3,911 4,986 liabilities.
This relates to the present value of the estimated amount Borrowings repayable within one year 2,825 4,129 payable by us in the event of full exercise of Novartis right to require Borrowings repayable after one year 14,264 14,661 us to acquire its 36.5% shareholding in the Consumer Healthcare Joint Venture.
As this option became exercisable from 2 March 2018, Net debt 13,178 13,804 with payment likely to be due several months after exercise, it has At 31 December 2017, net debt was 13.2 billion, compared been classified within current liabilities on the Group balance sheet.
with 13.8 billion at 31 December 2016, comprising gross debt Further details are provided in Note 3, Key accounting judgements of 17.1 billion and cash and liquid investments of 3.9 billion.
The decrease in net debt primarily reflected the improved free cash flow of 3.4 billion, disposal proceeds of 0.6 billion, together with Provisions a 0.6 billion favourable exchange impact from the translation of We carried deferred tax provisions and other short-term and non-Sterling denominated debt, which more than offset the cost non-current provisions of 2,661 million at 31 December 2017 of dividends paid to shareholders of 3.9 billion.
The decrease in the year primarily reflected a reduction in the deferred tax provision as a result of Swiss tax At 31 December 2017, our cash and liquid investments were held reform.
Other provisions at the year-end include 186 million as follows: 2016 344 million related to legal and other disputes and 2017 2016 504 million 2016 554 million related to the major restructuring m m programme.
Provision has been made for legal and other disputes, Bank balances and deposits 1,715 2,583 indemnified disposal liabilities, employee related liabilities and the US Treasury and Treasury repo costs of the restructuring programme to the extent that at the balance only money market funds 1,715 2,248 sheet date a legal or constructive obligation existed and could be Liquidity funds 403 66 reliably estimated.
Cash and cash equivalents 3,833 4,897 Liquid investments Government securities 78 89 3,911 4,986 Cash and liquid investments of 2.5 billion 2016 3.2 billion were held centrally at 31 December 2017.
74 GSK Annual Report 2017 Group financial review continued Financial position and resources continued Maturity profile of gross debt Maturity profile of gross debt m equivalent 4,500 4,000 3,500 3,000 2,500 2,000 1,500 1,000 500 0 2018 2019 2020 2022 2023 2024 2025 2026 2027 2029 2033 2034 2038 2039 2042 2043 2045 GBP bonds EUR bonds USD bonds Commercial paper Other bank borrowings Leases The analysis of cash and gross debt after the effects of hedging Total equity is as follows.
At 31 December 2017, total equity had decreased from 4,963 million at 31 December 2016 to 3,489 million.
This primarily 2017 2016 reflected the impact of the dividends paid exceeding the Total profit m m for the year offset by favourable exchange translation impact from the Cash and liquid investments 3,911 4,986 weaker Sterling rates.
The Total profit for the year was impacted by Gross debt fixed 16,229 17,288 the charge in respect of US tax reform.
floating 805 1,496 A summary of the movements in equity is set out below.
non-interest bearing 55 6 Net debt 13,178 13,804 2017 2016 m m Total equity at beginning of year 4,963 8,878 Movements in net debt Total comprehensive income for the year 2,882 2,024 Dividends to shareholders 3,906 4,850 2017 2016 m m Ordinary shares issued 56 89 Net debt at beginning of year 13,804 10,727 Changes in non-controlling interests 2 32 Decrease increase in cash and bank overdrafts 905 1,164 Recognition of liabilities with non-controlling interests 2,172 Increase in liquid investments 4 fide-recognition of liabilities with non-controlling Increase in long-term loans 2,233 interests 1,244 Net repayment of increase in short-term loans 3,200 148 Shares acquired by ESOP Trusts 65 74 Exchange movements 585 1,781 Share-based incentive plans 333 319 Other movements 17 16 Tax on share-based incentive plans 4 7 Net debt at end of year 13,178 13,804 Contributions from non-controlling interests 21 Distributions to non-controlling interests 789 534 Total equity at end of year 3,489 4,963 75 GSK Annual Report 2017 Strategic report Governance and remuneration Financial statements Investor information Financial position and resources continued Share purchases We have entered into a number of research collaborations to develop In 2017, the Employee Share Ownership Plan ESOP Trusts new compounds with other pharmaceutical companies.
The terms acquired 65 million of shares in GlaxoSmithKline plc 2016 of these arrangements can include upfront fees, equity investments, 74 million.
Shares are held by the Trusts to satisfy future exercises loans and commitments to fund specified levels of research.
In of options and awards under the Group share option and award addition, we will often agree to make further payments if future schemes.
A proportion of the shares held by the Trusts are in milestones are achieved.
respect of awards where the rules of the scheme require us to As some of these agreements relate to compounds in the early satisfy exercises through market purchases rather than the issue stages of development, the potential obligation to make milestone of new shares.
The shares held by the Trusts are matched to payments will continue for a number of years if the compounds move options and awards granted.
successfully through the development process.
Generally, the closer At 31 December 2017, the ESOP Trusts held 66.7 million the product is to marketing approval, the greater the probability 2016 43 million GSK shares against the future exercise of of success.
The amounts shown above within intangible assets share options and share awards.
The carrying value of 400 million represent the maximum that would be paid if all milestones were 2016 286 million has been deducted from other reserves.
The achieved, and include 4.5 billion which relates to externalised market value of these shares was 882 million 2016 667 million.
projects in the discovery portfolio.
There was a reduction in the commitments in 2017 due to amendments made to existing During 2017, no shares were repurchased.
At 31 December 2017, agreements and obligations which have ceased.
we held 414.6 million shares as Treasury shares 2016 458.2 million shares, at a cost of 5,800 million 2016 6,451 million, In 2016, we reached an agreement with the trustees of the UK which has been deducted from retained earnings.
pension schemes to make additional contributions, including in 2016, to assist in eliminating the pension deficit identified as part of the No ordinary shares were purchased in the period 1 January 2018 31 December 2014 actuarial funding valuation.
The table above to 12 March 2018 and the company does not expect to make any includes this commitment but excludes the normal ongoing annual ordinary share repurchases in the remainder of 2018. funding requirement in the UK of approximately 130 million.
For further information on pension obligations, see Note 28 to the Commitments and contingent liabilities financial statements, Pensions and other post-employment benefits.
Financial commitments are summarised in Note 41 to the financial statements, Commitments.
Other contingent liabilities and Contingent liabilities obligations in respect of short and long-term debt are set out in The following table sets out contingent liabilities, comprising Note 32 to the financial statements, Contingent liabilities and discounted bills, performance guarantees, letters of credit and other Note 31 to the financial statements, Net debt.
items arising in the normal course of business, and when they are Amounts provided for pensions and post-retirement benefits are expected to expire.
set out in Note 28 to the financial statements, Pensions and other Total Under 1 yr 1-3 yrs 3-5 yrs 5 yrs post-employment benefits.
Amounts provided for restructuring m m m m m programmes and legal, environmental and other disputes are set Guarantees 315 151 127 31 6 out in Note 29 to the financial statements, Other provisions.
Other contingent liabilities 119 17 61 3 38 Contractual obligations and commitments Total 434 168 188 34 44 The following table sets out our contractual obligations and commitments at 31 December 2017 as they fall due for payment.
In the normal course of business, we have provided various indemnification guarantees in respect of business disposals in Total Under 1 yr 1-3 yrs 3-5 yrs 5 yrs which legal and other disputes have subsequently arisen.
A provision m m m m m is made where an outflow of resources is considered probable and Loans 17,137 2,802 2,422 1,499 10,414 a reliable estimate can be made of the likely outcome of the dispute Interest on loans 8,510 555 985 956 6,014 and this is included in Note 29 to the financial statements, Other Finance lease obligations 66 23 35 3 5 provisions.
Finance lease charges 12 2 3 2 5 We provide for the outcome of tax, legal and other disputes when an Operating lease outflow of resources is considered probable and a reliable estimate commitments 1,045 186 271 201 387 of the outflow may be made.
At 31 December 2017, other than for Intangible assets 5,254 205 546 750 3,753 those disputes where provision has been made, it was not possible Property, plant & equipment 584 527 51 6 to make a reliable estimate of the potential outflow of funds that might Investments 107 34 47 26 be required to settle disputes where the possibility of there being an outflow was more than remote.
Purchase commitments 346 284 23 17 22 Pensions 738 123 246 246 123 The ultimate liability for such matters may vary significantly from the Other commitments 38 18 20 amounts provided and is dependent upon the outcome of litigation proceedings and negotiations with the relevant tax authorities.
This Total 33,837 4,759 4,649 3,706 20,723 is discussed further in Principal risks and uncertainties on pages Commitments in respect of loans and future interest payable on loans 257 to 266 and Notes 14 and 45 to the financial statements, are disclosed before taking into account the effect of derivatives.
76 GSK Annual Report 2017 Group financial review continued Critical accounting policies The consolidated financial statements are prepared in accordance A reconciliation of gross turnover to net turnover for the US with IFRS, as adopted for use in the European Union, and also Pharmaceuticals business, including Puerto Rico, is as follows: with IFRS as issued by the IASB, following the accounting policies 2017 2016 2015 approved by the Board and described in Note 2 to the financial Margin Margin Margin statements, Accounting principles and policies.
m % m % m % Gross turnover 16,365 100 13,363 100 10,093 100 We are required to make estimates and assumptions that affect the amounts of assets, liabilities, revenue and expenses reported Market driven in the financial statements.
Actual amounts and results could differ segments 4,058 25 2,749 21 1,761 17 from those estimates.
Government mandated and The critical accounting policies relate to the following areas: state programs 3,938 24 3,070 23 2,357 23 Turnover Cash discounts 330 2 261 2 192 2 Taxation Note 14 Customer returns 97 1 98 1 93 1 Legal and other disputes Notes 29 and 45 Prior year adjustments 86 1 109 1 142 1 Other items 460 3 457 3 298 3 Intangible asset impairments Note 19 Total deductions 8,797 54 6,526 49 4,559 45 Business combinations Note 38 Net turnover 7,568 46 6,837 51 5,534 55 Pensions and other post-employment benefits Note 28.
Information on the judgements and estimates made in these areas Market driven segments consist primarily of Managed Care and is given in Note 3 to the financial statements, Key accounting Medicare plans with which GSK negotiates contract pricing that judgements and estimates.
is honoured via rebates and chargebacks.
Mandated segments consist primarily of Medicaid and Federal Government programmes Turnover which receive government mandated pricing via rebates and In respect of the Turnover accounting policy, our largest business chargebacks.
is US Pharmaceuticals, and the US market has the most complex The increased deductions in the market driven segments of the arrangements for rebates, discounts and allowances.
The following gross turnover to net turnover reconciliation primarily reflected briefly describes the nature of the arrangements in existence in our higher rebates and chargebacks on Respiratory products, and US Pharmaceuticals business: on Advair in particular.
During 2017, Advair accounted for 21% We have arrangements with certain indirect customers whereby of US Pharmaceuticals turnover and approximately 40% of the total the customer is able to buy products from wholesalers at reduced deduction for rebates and returns, and the Respiratory portfolio as prices.
A chargeback represents the difference between the a whole accounted for approximately 82% of the total deduction invoice price to the wholesaler and the indirect customers in the year.
Advair continued to suffer pricing pressures in 2017 contractual discounted price.
Accruals for estimating chargebacks as the business sought to transition its Respiratory portfolio to are calculated based on the terms of each agreement, historical newer products.
experience and product growth rates The balance sheet accruals for rebates, discounts, allowances Customer rebates are offered to key managed care and Group and returns for the US Pharmaceuticals and Vaccines businesses Purchasing Organisations GPO and other direct and indirect are managed on a combined basis.
These arrangements require the customer to achieve total accrual amounted to 2,837 million 2016 2,218 million.
certain performance targets relating to the value of product purchased, formulary status or pre-determined market shares A monthly process is operated to monitor inventory levels at relative to competitors.
The accrual for customer rebates is wholesalers for any abnormal movements.
This process uses estimated based on the specific terms in each agreement, gross sales volumes, prescription volumes based on third party historical experience and product growth rates data sources and information received from key wholesalers.
The aim of this is to maintain inventories at a consistent level from year The US Medicaid programme is a state-administered programme to year based on the pattern of consumption.
providing assistance to certain poor and vulnerable patients.
In 1990, the Medicaid Drug Rebate Program was established to On this basis, US Pharmaceuticals and Vaccines inventory levels at reduce State and Federal expenditure on prescription drugs.
In wholesalers and in other distribution channels at 31 December 2017 2010, the Patient Protection and Affordable Care Act became law.
were estimated to amount to approximately four weeks of turnover.
We participate by providing rebates to states.
Accruals for Medicaid This calculation uses third party information, the accuracy of which rebates are calculated based on the specific terms of the relevant cannot be totally verified, but is believed to be sufficiently reliable for regulations or the Patient Protection and Affordable Care Act this purpose.
Cash discounts are offered to customers to encourage prompt payment.
These are accrued for at the time of invoicing and adjusted subsequently to reflect actual experience We record an accrual for estimated sales returns by applying historical experience of customer returns to the amounts invoiced, together with market related information such as stock levels at wholesalers, anticipated price increases and competitor activity.
77 GSK Annual Report 2017 Strategic report Governance and remuneration Financial statements Investor information Critical accounting policies continued Legal and other disputes Like many pharmaceutical companies, we are faced with various In respect of the accounting policy for Legal and other disputes, complex product liability, anti-trust and patent litigation, as well as the following briefly describes the process by which we determine investigations of its operations conducted by various governmental the level of provision that is necessary.
Throughout the year, the General Counsel of the Group, as head of the Groups legal function, and the Senior In accordance with the requirements of IAS 37, Provisions, Vice President and Head of Global Litigation for the Group, who is contingent liabilities and contingent assets, we provide for responsible for all litigation and government investigations, routinely anticipated settlement costs where an outflow of resources is brief the Chief Executive Officer, the Chief Financial Officer and the considered probable and a reliable estimate may be made of the Board of Directors on the significant litigation pending against the likely outcome of the dispute and legal and other expenses arising Group and governmental investigations of the Group.
from claims against the Group.
We may become involved in significant legal proceedings, in respect of which it is not possible These meetings, as appropriate, detail the status of significant litigation to make a reliable estimate of the expected financial effect, if any, and government investigations and review matters such as the number that could result from ultimate resolution of the proceedings.
In these of claims notified to us, information on potential claims not yet notified, cases, appropriate disclosure about such cases would be included assessment of the validity of claims, progress made in settling claims, in the Annual Report, but no provision would be made.
recent settlement levels and potential reimbursement by insurers.
This position could change over time and, therefore, there can be no The meetings also include an assessment of whether or not there assurance that any losses that result from the outcome of any legal is sufficient information available for us to be able to make a reliable proceedings will not exceed by a material amount the amount of the estimate of the potential outcomes of the disputes.
Often, external provisions reported in the Groups financial statements.
counsel assisting us with various litigation matters and investigations will also assist in the briefing of the Board and senior management.
Following these discussions, for those matters where it is possible to make a reliable estimate of the amount of a provision, if any, that may be required, the level of provision for legal and other disputes is reviewed and adjusted as appropriate.
These matters are discussed further in Note 45 to the financial statements, Legal proceedings.
Treasury policies Capital management We report in Sterling and pay dividends out of Sterling cash flows.
Our financial strategy, implemented through the Groups Financial The role of Treasury is to monitor and manage the Groups external architecture, supports GSKs strategic priorities and it is regularly and internal funding requirements and financial risks in support of reviewed by the Board.
We manage the capital structure of the our strategic objectives.
GSK operates on a global basis, primarily Group through an appropriate mix of debt and equity.
through subsidiary companies, and we manage our capital to ensure that our subsidiaries are able to operate as going concerns and to GSKs long-term credit rating with Standard and Poors is A optimise returns to shareholders through an appropriate balance stable outlook and with Moodys Investor Services Moodys of debt and equity.
Treasury activities are governed by policies is A2 stable outlook.
Our short-term credit ratings are A-1 and P-1 approved annually by the Board of Directors, and most recently with Standard and Poors and Moodys respectively.
A Treasury Management Group TMG meeting, chaired by our Chief Financial Officer, takes place on a regular Liquidity risk management basis to review treasury activities.
Its members receive management Our policy is to borrow centrally in order to meet anticipated funding information relating to these activities.
Our cash flow forecasts and funding requirements are monitored by the TMG on a regular basis.
Our strategy is to diversify Treasury operations liquidity sources using a range of facilities and to maintain broad The objective of our Treasury activity is to minimise the post-tax net access to financial markets.
cost of financial operations and reduce its volatility in order to benefit Each day, we sweep cash from a number of global subsidiaries earnings and cash flows.
We use a variety of financial instruments to to central Treasury accounts for liquidity management purposes.
finance our operations and derivative financial instruments to manage market risks from these operations.
These derivatives, principally Interest rate risk management comprising interest rate swaps, foreign exchange forward contracts Our objective is to minimise the effective net interest cost and and swaps, are used to swap borrowings and liquid assets into to balance the mix of debt at fixed and floating interest rates over currencies required for Group purposes and to manage exposure time.
The policy on interest rate risk management limits the amount to financial risks from changes in foreign exchange rates and of floating interest payments to a prescribed percentage of interest rates.
We do not hold or issue derivatives for speculative purposes and GSKs Treasury policies specifically prohibit such activity.
All transactions in financial instruments are undertaken to manage the risks arising from underlying business activities.
78 GSK Annual Report 2017 Group financial review continued Treasury policies continued Foreign exchange risk management Borrowings denominated in, or swapped into, foreign currencies Foreign currency transaction exposures arising on external trade that match investments in overseas Group assets may be treated flows are not normally hedged.
Foreign currency transaction as a hedge against the relevant assets.
Forward contracts in major exposures arising on internal trade flows are selectively hedged.
currencies are also used to reduce exposure to the Groups Our objective is to minimise the exposure of overseas operating investment in overseas Group assets.
The TMG reviews the subsidiaries to transaction risk by matching local currency income ratio of borrowings to assets for major currencies regularly.
with local currency costs where possible.
GSKs internal trading Counterparty risk management transactions are matched centrally and we manage inter-company We set global counterparty limits for each of our banking and payment terms to reduce foreign currency risk.
Foreign currency investment counterparties based on long-term credit ratings from cash flows can be hedged selectively under the management of Moodys and Standard and Poors.
Treasurys usage of these limits Treasury and the TMG.
These include hedges of the foreign is monitored daily by a Corporate Compliance Officer CCO who exchange risk arising from acquisitions and disposals of assets.
Any breach of these limits would Where possible, we manage the cash surpluses or borrowing be reported to the CFO immediately.
requirements of subsidiary companies centrally using forward contracts to hedge future repayments back into the originating The CCO also monitors the credit rating of these counterparties and, currency.
when changes in ratings occur, notifies Treasury so that changes can be made to investment levels or to authority limits as appropriate.
In order to reduce foreign currency translation exposure, we seek In addition, relationship banks and their credit ratings are reviewed to denominate borrowings in the currencies of our principal assets regularly and a report is presented annually to the TMG for approval.
These are primarily denominated in US Dollars, Euros and Sterling.
Borrowings can be swapped into other currencies as required.
Strategic report The Strategic report was approved by the Board of Directors on 12 March 2018 and signed on its behalf by: Simon Dingemans Chief Financial Officer 12 March 2018
